Pediatric Tumefactive Multiple Sclerosis Case Report and Literature Review: A Saudi Experience

CASE REPORT
Muhannad Alanazi, Raed AlRuwaili

 
For citation: Alanazi M, Raed AlRuwaili R. Pediatric Tumefactive Multiple Sclerosis Case Report and Literatures Review: A Saudi Experience. International Journal of Biomedicine. 2025;15(3):590-593. doi:10.21103/Article15(3)_CR1
 
Originally published September 5, 2025

Abstract: 

Tumefactive demyelinating lesions (TDLs) are rare, mass-like lesions that present a significant diagnostic challenge, often mimicking brain tumors on magnetic resonance imaging (MRI). This case report describes a 9-year-old male who presented with progressive neurological symptoms, including persistent headaches, ataxia, and dysarthria. MRI findings raised concerns for both demyelinating and neoplastic processes, but a biopsy confirmed the diagnosis of tumefactive multiple sclerosis (TMS). The patient was successfully treated with high-dose corticosteroids, resulting in marked clinical improvement. This case emphasizes the importance of differentiating TDLs from neoplasms, particularly in pediatric patients, and highlights the role of biopsy and advanced imaging techniques in achieving an accurate diagnosis. Long-term follow-up with disease-modifying therapies is crucial to prevent relapse and progression.

Keywords: 
tumefactive demyelinating lesions • multiple sclerosis • corticosteroid therapy • brain tumor
References: 
  1. Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017 May;14:72-79. doi: 10.1016/j.msard.2017.04.003. Epub 2017 Apr 9. PMID: 28619436.
  2. Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Brück W. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008 Jul;131(Pt 7):1759-75. doi: 10.1093/brain/awn098. Epub 2008 Jun 5. PMID: 18535080; PMCID: PMC2442427.
  3. Höftberger R, Lassmann H. Tumefactive demyelination in multiple sclerosis and other demyelinating diseases. Handbook of Clinical Neurology. 2017;145:417-432. doi: 10.1016/B978-0-12-802395-2.00037-5
  4. Suh CH, Kim HS, Jung SC, Choi CG. Tumefactive demyelinating lesions: The usefulness of conventional MRI features in differentiating from glioma and primary central nervous system lymphoma. European Radiology. 2018;28(4):1396–1405. doi: 10.1007/s00330-017-5094-1
  5. Tremblay MÉ, Lecours C, Samson L, Sánchez-Sánchez SM, Matarazzo V. Tumefactive demyelinating lesions: Review of pathophysiological mechanisms and role of glial cells. Progress in Neurobiology. 2017;153:153-172. doi: 10.1016/j.pneurobio.2017.06.007
  6. Hiremath SB, Saisooraj S, Mahadevan A, Yadav R, Narayan S. Tumefactive demyelination versus glioma: Can MR perfusion help differentiate? Journal of Neuroradiology. 2017;44(6):387-394. doi: 10.1016/j.neurad.2017.03.001
  7. Magaña SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, Rodriguez M, Thomsen K, Weigand S, Mandrekar J, Linbo L, Lucchinetti CF. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011 Jul;68(7):870-8. doi: 10.1001/archneurol.2011.34. Epub 2011 Mar 14. PMID: 21403003; PMCID: PMC3134547.
  8. Brod SA, Brod MA, Weinstein R. Diagnosis and treatment of tumefactive multiple sclerosis. Journal of Clinical Neuroscience. 2019;66:90-96. doi:10.1016/j.jocn.2019.03.006
  9. van Langelaar J, Rijvers L, Smolders J, van Luijn MM. B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers. Front Immunol. 2020 May 8;11:760. doi: 10.3389/fimmu.2020.00760. PMID: 32457742; PMCID: PMC7225320.
  10. Parnell GP, Booth DR. The genetics of multiple sclerosis. Multiple Sclerosis and Related Disorders. 2017;13:18-25. doi: 10.1016/j.msard.2017.01.013
  11. De Silvestri A, Capittini C, Mallucci G, Bergamaschi R, Rebuffi C, Pasi A, Martinetti M, Tinelli C. The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Dis Markers. 2019 Nov 6;2019:1409069. doi: 10.1155/2019/1409069. PMID: 31781296; PMCID: PMC6875418.
  12. Villarreal JV, Abraham MJ, Acevedo JAG, Rai PK, Thottempudi N, Fang X, Gogia B. Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS. Mult Scler Relat Disord. 2021 Feb;48:102699. doi: 10.1016/j.msard.2020.102699. Epub 2020 Dec 26. PMID: 33373797.
  13. Fereidan-Esfahani M, Decker PA, Weigand SD, Lopez Chiriboga AS, Flanagan EP, Tillema JM, Lucchinetti CF, Eckel-Passow JE, Tobin WO. Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients. Ann Clin Transl Neurol. 2023 Sep;10(9):1544-1555. doi: 10.1002/acn3.51844. Epub 2023 Jul 13. PMID: 37443413; PMCID: PMC10502639.
  14. Ongphichetmetha T, Aungsumart S, Siritho S, Apiwattanakul M, Tanboon J, Rattanathamsakul N, Prayoonwiwat N, Jitprapaikulsan J. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Sci Rep. 2024 Jan 16;14(1):1426. doi: 10.1038/s41598-024-52048-w. Erratum in: Sci Rep. 2024 Mar 4;14(1):5332. doi: 10.1038/s41598-024-56016-2. PMID: 38228919; PMCID: PMC10791607.
  15. Codjia P, Zivadinov R, Gandhi S, Durfee J, Weinstock-Guttman B. Tumefactive MS and risk of conversion to relapsing multiple sclerosis. Journal of Neuroimmunology.2019;332: 132-138. doi:10.1016/j.jneuroim.2019.04.004
  16. Altintas A, Petek B, Isik N, Terzi M, Bolukbasi F, Tavsanli M, Saip S, Boz C, Aydin T, Arici-Duz O, Ozer F, Siva A. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. Mult Scler. 2012 Oct;18(10):1448-53. doi: 10.1177/1352458512438237. Epub 2012 Mar 14. PMID: 22419670.
  17. Giussani C, Falini A, Cadioli M, Marotta G. Diffusion tensor MRI for primary brain tumor characterization. Neurosurgical Review. 2010;33(3):251-259. doi:10.1007/s10143-010-0267-1
  18. Palanichamy A, Chakravarti A. Metabolic and diffusion MRI features in tumor vs. non-tumor lesions: Evaluation of diagnostic tools. Neuroradiology. 2017;59(5):487-493. doi: 10.1007/s00234-017-1824-3
  19. Sato DK, Nakashima I, Takahashi T. Rebound syndrome following discontinuation of fingolimod therapy in patients with multiple sclerosis. Neurology. 2018;90(3):e157-e163. doi: 10.1212/WNL.0000000000004853

Download Article
Received May 17, 2025.
Accepted June 16, 2025.
©2025 International Medical Research and Development Corporation.